EFFECTS OF TELMISARTAN ON OXIDATIVE STRESS LEVEL, VASCULAR ENDOTHELIAL FUNCTION, INFLAMMATORY RESPONSE AND ADHESION MOLECULES IN PATIENTS WITH HYPERTENSION

Yuancai Xiang*, #, Chun Yan**, Biao Tan**, Xingyu Yan***, Fenghua Li***, Jingming Tian****

1Department of Cardiology, Lichuan Traditional Chinese Medicine Hospital, Lichuan, PR China - 2Department of Gastroenterology, Lichuan Traditional Chinese Medicine Hospital, Lichuan, PR China - 3Department of Pharmacy, Lichuan Traditional Chinese Medicine Hospital, Lichuan, PR China - 4Department of Obstetrics and gynecology, Lichuan Traditional Chinese Medicine Hospital, Lichuan, PR China

Objective: To investigate the effects of telmisartan on the oxidative stress level, vascular endothelial function, inflammatory reaction and adhesion molecules in patients with hypertension.

Methods: A total of 96 outpatients with hypertension admitted in our hospital between December 2016 and December 2017 were selected as the subjects of the study. These patients were randomly divided into a study group (conventional treatment + telmisartan) and a control group (routine treatment + benazepril), with 48 patients in each group. After 6 months of treatment, the therapeutic effect, incidence of cardiovascular events, and levels of superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), endothelin-1 (ET-1), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF), vascular cell adhesion molecule (VCAM-1), intercellular adhesion molecule (ICAM-1), interleukin 6 (IL-6), tumour necrosis factor-α (TNF-α) and high sensitivity C-reactive protein (hs-CRP) were observed and compared between the two groups.

Results: The total effective rate in the control group (77.08%) was significantly lower than that in the study group (93.75%), and the difference was statistically significant (P<0.05). The incidence of cardiovascular events in the study group (4.17%) was significantly lower than that in the control group (20.83%), and there were statistical differences (P<0.05). Before treatment, there was no significant difference in the levels of SOD, MDA, NO, ET-1, VEGF, vWF, ICAM-1, VCAM-1, hs-CRP, IL-6, or TNF-α between the study group and the control group (P>0.05). After treatment, there were statistically significant differences in the levels of SOD, MDA, NO, ET-1, VEGF, vWF, ICAM-1, VCAM-1, hs-CRP, IL-6 and TNF-α in the study group compared with the levels before treatment (P<0.05). After treatment, there were statistically significant differences in the levels of SOD, MDA, NO, ET-1, VEGF, vWF, ICAM-1, VCAM-1, hs-CRP, IL-6 and TNF-α in the control group compared with the levels before treatment (P<0.05). After treatment, there was no statistically significant difference in the levels of hsCRP, IL-6 or TNF-α in the control group compared with the levels before treatment (P>0.05). After treatment, there were statistically significant differences in the levels of SOD, MDA, NO, ET-1, VEGF, vWF, ICAM-1, VCAM-1, hs-CRP, IL-6 and TNF-α between the study group and the control group (P<0.05).

Conclusion: Telmisartan is effective in the treatment of hypertension. Telmisartan is able to inhibit oxidative stress and inflammatory reactions, improving vascular endothelial function and increasing the levels of adhesion molecules. Furthermore, its safety is good.